TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03205891

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Cause of deathStaffing, sites or logistics, also funding or business Automatic label, confidence 0.6, unverified. How labels are made.
“Change in treatment priorities for these disease types as well as staffing concerns.”

The sponsor’s own words in the registry.

Life of this trial

201720182019Registered2017-06-29Withdrawn (as of)2018-01-17Planned start2018-03 (planned)

Vital statistics

Status
Withdrawn
Phase
Phase 1
Sponsor
M.D. Anderson Cancer Center
Sponsor type
University, hospital or other
Conditions
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; CD30+ Peripheral T-cell Lymphoma
Interventions
Brentuximab Vedotin; TAK228; Glucose Monitor
Participants
0

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.